In last trading session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw 0.49 million shares changing hands with its beta currently measuring 2.51. Company’s recent per share price level of $0.56 trading at -$0.02 or -3.45% at ring of the bell on the day assigns it a market valuation of $143.16M. That closing price of ADAP’s stock is at a discount of -266.07% from its 52-week high price of $2.05 and is indicating a premium of 5.36% from its 52-week low price of $0.53.

For Adaptimmune Therapeutics Plc ADR (ADAP), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.89. Splitting up the data highlights that, out of 6 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.15 in the current quarter.

Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information

Upright in the red during last session for losing -3.45%, in the last five days ADAP remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $0.56 price level, adding 8.0% to its value on the day. Adaptimmune Therapeutics Plc ADR’s shares saw a change of 3.86% in year-to-date performance and have moved -2.95% in past 5-day. Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) showed a performance of -2.64% in past 30-days.

Wall Street analysts have assigned a consensus price target of 3 to the stock, which implies a rise of 81.33% to its current value. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 4. It follows that stock’s current price would drop -78.57% in reaching the projected high whereas dropping to the targeted low would mean a loss of -78.57% for stock’s current value.

Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts

This year revenue growth is estimated to rise 204.78% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 8.77M for the same. And 3 analysts are in estimates of company making revenue of 6.3M in the next quarter. Company posted 231k and 5.68M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.30% during past 5 years.

Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s Major holders

MATRIX CAPITAL MANAGEMENT COMPANY, LP is the top institutional holder at ADAP for having 38.97 million shares of worth $38.0 million. And as of 2024-06-30, it was holding 2.5415 of the company’s outstanding shares.

The second largest institutional holder is BANK OF AMERICA CORP /DE/, which was holding about 4.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 1.9239 of outstanding shares, having a total worth of $4.53 million.

On the other hand, SPDR Portfolio Developed World ex-US ETF and SEI Institutional International Tr-International Equity are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 251.08 shares of worth $0.14 million or 0.10% of the total outstanding shares. The later fund manager was in possession of 175.24 shares on Nov 30, 2024 , making its stake of worth around $98048.0 in the company or a holder of 0.07% of company’s stock.